Skip to main content

RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 7, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Nov. 7, 2024 -- For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters, according to a study published online Oct. 19 in The Lancet.

Amanda B. Payne, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues assessed the effectiveness of RSV vaccines against RSV-associated hospitalizations and emergency department encounters among adults aged 60 years or older who underwent virus testing from Oct. 1, 2023, to March 31, 2024.

The researchers found that vaccine effectiveness was 80 and 81 percent against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness among adults aged 60 years or older without immunocompromising conditions. Vaccine effectiveness was 73 percent against associated hospitalizations among 8,435 hospitalizations in adults with immunocompromising conditions. Vaccine effectiveness was 77 percent against RSV-associated emergency department encounters among 36,521 emergency department encounters for RSV-like illness among adults aged 60 years or older without an immunocompromising condition.

"These findings provide additional context regarding the benefit of respiratory syncytial virus vaccination among adults aged at least 60 years," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted November 2024

Read this next

Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization

WEDNESDAY, May 28, 2025 -- Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event compared with COVID-19...

RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization

TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...

Nirsevimab Effective for Reducing Burden of RSV in Infants

THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.